Harmony Asset Management LLC Has $432,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Harmony Asset Management LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 18.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,931 shares of the biopharmaceutical company’s stock after purchasing an additional 2,309 shares during the period. Harmony Asset Management LLC’s holdings in Pfizer were worth $432,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. HighTower Advisors LLC raised its position in shares of Pfizer by 5.2% in the third quarter. HighTower Advisors LLC now owns 3,219,490 shares of the biopharmaceutical company’s stock valued at $93,146,000 after purchasing an additional 157,775 shares during the period. Hilltop Holdings Inc. lifted its position in Pfizer by 31.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 102,353 shares of the biopharmaceutical company’s stock worth $2,962,000 after acquiring an additional 24,736 shares during the last quarter. Hollow Brook Wealth Management LLC boosted its holdings in Pfizer by 4.9% during the third quarter. Hollow Brook Wealth Management LLC now owns 66,602 shares of the biopharmaceutical company’s stock valued at $1,927,000 after acquiring an additional 3,137 shares during the period. Cladis Investment Advisory LLC grew its position in shares of Pfizer by 2.2% in the third quarter. Cladis Investment Advisory LLC now owns 58,138 shares of the biopharmaceutical company’s stock valued at $1,683,000 after purchasing an additional 1,228 shares during the last quarter. Finally, Ascent Group LLC lifted its position in shares of Pfizer by 23.3% during the 3rd quarter. Ascent Group LLC now owns 62,712 shares of the biopharmaceutical company’s stock worth $1,815,000 after purchasing an additional 11,867 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PFE shares. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Citigroup initiated coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.82 on Tuesday. The company has a market capitalization of $146.32 billion, a price-to-earnings ratio of 34.89, a P/E/G ratio of 0.71 and a beta of 0.65. The company has a 50 day simple moving average of $27.83 and a two-hundred day simple moving average of $28.49. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the firm earned ($0.17) EPS. The firm’s revenue was up 31.2% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were given a dividend of $0.42 per share. The ex-dividend date was Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.51%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.